HIV and thrombosis: a review.
The array of clinicopathologic factors associated with acquired immune deficiency syndrome (AIDS) patients continues to increase and surprise many physicians. The recent literature contains reports of thrombotic episodes occurring in patients with human immunodeficiency virus (HIV) infection. Various abnormalities predisposing to a hypercoagulable state have also been reported in AIDS patients including the presence of antiphospholipid antibodies and the lupus anticoagulant; deficiencies of protein C, protein S, heparin cofactor II, and antithrombin and increased levels of von Willebrand factor, and d-dimers. These abnormalities correlate with the severity of HIV-associated immunosuppression as measured by the CD4 cell counts and with the presence of concurrent infectious or neoplastic diseases. The authors reviewed the medical literature and describe various abnormalities predisposing to a hypercoagulable state in AIDS patients along with the management of such complications. This issue is important because deep venous thrombosis (DVT), pulmonary embolus (PE), or thrombosis at other sites can develop in patients with AIDS who are ambulatory and have no known risk factors for pathologic thrombus formation, providing another challenge in an already difficult clinical situation. This also provides a strong rationale for careful prospective studies focusing on the prevalence and risk factors involved in the development of thromboembolic complications in patients with AIDS.
Saif
M W
MW
National Cancer Institute, National Institute of Health, Bethesda, Maryland 20889, USA. saifw@mail.nih.gov
Greenberg
B
B
D017088:AIDS-Related Opportunistic Infections / Q000097:blood*; D000925:Anticoagulants / Q000627:therapeutic use; D020147:Coagulation Protein Disorders / Q000209:etiology*; D015658:HIV Infections / Q000097:blood* / Q000150:complications; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D011480:Protease Inhibitors; D014859:Warfarin; D006493:Heparin